Search
National Societies and EHA join forces for Ukraine
The European Hematology Association (EHA) and the European National Societies for Hematology want to express again, and publicly, their profound solidarity with the Ukrainian Hematology Society, and with Ukrainian hematology patients and their families.
Read moreEHA welcomes European Parliament backing for SoHO legislation
EHA welcomes the European Parliament’s backing for SoHO legislation that puts patient safety and supply sustainability first.
Read moreBelgium shares EU health priorities for Council Presidency
On December 8, Belgium held a conference to unveil its program for the upcoming Council of the EU Presidency (website), to start on January 1, 2024.
Read moreEuropean Scientific foundation for Laboratory Hemato Oncology (ESLHO)
The objectives of ESLHO are to promote the continuous innovation and standardization of laboratory diagnostics focused on lymphoid malignancies, as well as to facilitate quality control and education in this field.
Read moreUpdate on EU4Health Calls and Contracts for 2024
The European Health and Digital Executive Agency (HaDEA) has published the tentative calendar for the EU4Health program calls and contracts for 2024.
Read moreFrom Plans to Action: European Cancer Summit
From Plans to Action: European Cancer Summit (Brussels-Hybrid, November 17-18, 2021)
November 17- 18 marks the first anniversary of EHA’s membership to the European Cancer Organisation (ECO), as well as the event dates for the 2021 European Cancer Summit.
PRESS RELEASE: The future of research in hematology is here
“For the first time, hematologists in Europe came together to develop a roadmap to guide hematology research in Europe” says Professor Andreas Engert, chair of the EHA Research Roadmap Task Force, “Hematology in Europe has achieved a lot, but the discipline must focus and…
Read morePosition of EHA on Research Funding
The challenge
The cost of biomedical research is great, but the cost of disease is immense. An ageing population and expensive innovations in medicine put an increasing burden on already stressed healthcare budgets.
ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.
Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.
Read moreTraining vital for new era of patient-centric healthcare
Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- »